GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » Shiller PE Ratio

Antares Pharma (Antares Pharma) Shiller PE Ratio : (As of May. 05, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Antares Pharma Shiller PE Ratio Historical Data

The historical data trend for Antares Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Shiller PE Ratio Chart

Antares Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Antares Pharma Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Antares Pharma's Shiller PE Ratio

For the Medical Instruments & Supplies subindustry, Antares Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antares Pharma's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Antares Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Shiller PE Ratio falls into.



Antares Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Antares Pharma's E10 for the quarter that ended in Mar. 2022 is calculated as:

For example, Antares Pharma's adjusted earnings per share data for the three months ended in Mar. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2022 (Change)*Current CPI (Mar. 2022)
=-0.01/121.3010*121.3010
=-0.010

Current CPI (Mar. 2022) = 121.3010.

Antares Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201206 -0.030 96.819 -0.038
201209 -0.030 97.633 -0.037
201212 -0.040 96.871 -0.050
201303 -0.030 98.209 -0.037
201306 -0.040 98.518 -0.049
201309 -0.050 98.790 -0.061
201312 -0.040 98.326 -0.049
201403 -0.070 99.695 -0.085
201406 -0.070 100.560 -0.084
201409 -0.050 100.428 -0.060
201412 -0.080 99.070 -0.098
201503 -0.050 99.621 -0.061
201506 -0.010 100.684 -0.012
201509 -0.040 100.392 -0.048
201512 -0.040 99.792 -0.049
201603 -0.050 100.470 -0.060
201606 -0.040 101.688 -0.048
201609 -0.040 101.861 -0.048
201612 -0.030 101.863 -0.036
201703 -0.030 102.862 -0.035
201706 -0.020 103.349 -0.023
201709 -0.030 104.136 -0.035
201712 -0.020 104.011 -0.023
201803 -0.040 105.290 -0.046
201806 -0.030 106.317 -0.034
201809 -0.010 106.507 -0.011
201812 0.040 105.998 0.046
201903 -0.030 107.251 -0.034
201906 -0.010 108.070 -0.011
201909 0.010 108.329 0.011
201912 0.030 108.420 0.034
202003 -0.010 108.902 -0.011
202006 0.010 108.767 0.011
202009 0.030 109.815 0.033
202012 0.300 109.897 0.331
202103 0.020 111.754 0.022
202106 0.030 114.631 0.032
202109 0.030 115.734 0.031
202112 0.190 117.630 0.196
202203 -0.010 121.301 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Antares Pharma  (NAS:ATRS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Antares Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma (Antares Pharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart director C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson officer: See Remarks 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity director
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham officer: See Remarks 315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth director
Robert F Apple director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson director
Jacques Gonella director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi officer: EVP, Chief Medical Officer 106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447